HENDERSON, Nev.–(BUSINESS WIRE)– 3PEA International, Inc. (OTCQB:TPNL), a vertically integrated provider of innovative prepaid card programs and processing services for corporate, consumer and government applications, is delighted to announce the addition of Bio/Pharma copay offset and reimbursement industry veteran Al Negron to its executive team as Senior Vice President Business Development in charge of 3PEA’S Healthcare vertical.
Al is a veteran of the Bio/Pharmaceutical services industry with a record of over 25 years of success and achievement in accelerating revenue growth, increasing profitability and expanding market footprints for his Bio/Pharmaceutical clients. Al has consulted with some of the most successful brand launch teams and product manufacturers including Alcon, Allergan, Eli Lilly, Novartis, Mylan and Pfizer. As an early employee of PSKW, LLC (now ConnectiveRx), Al was prominently involved with that company’s growth and accomplishments, and in conjunction with 3PEA International, pioneered the use of prepaid cards as an immediate payment reimbursement solution for companies such as Alcon, Genzyme, Actavis, UCB and others. In his new role, Al is responsible for managing and developing new products and revenue streams for 3PEA’s Healthcare vertical with special focus on Bio/Pharma copay offset and reimbursement products in support of pharmaceutical copay marketing organizations.
Copay offset and reimbursement products are utilized by millions of prescription holders nationwide to help make prescription drugs and therapies more affordable. Sponsored by Bio/Pharma companies, it is estimated that more than $7 billion per year is processed through these reimbursement products in the US alone.
“Al is uniquely suited for the leadership role he will assume at 3PEA International” said Mark Newcomer, Chief Executive Officer, 3PEA International. “Al brings to 3PEA a wide-ranging creative and leadership background spanning from military service as a logistician and detachment commander, to manufacturing, quality, marketing and sales. Moreover, Al’s depth of experience with prepaid card solutions and immediate payment vehicles as reimbursement tools adds immediate value to our Bio/Pharma initiatives in support of our management, processing services and reimbursement card products. We are confident that Al’s experience and knowledge will be instrumental in expanding 3PEA’s role in this expansive market.”
About 3PEA International
3PEA International (OTCQB:TPNL) is an experienced and trusted prepaid card payment solutions provider as well as an integrated payment processor that has managed millions of prepaid cards in its portfolio. Through its PaySign brand, 3PEA conceptualizes, develops and manages payment solutions, prepaid card programs, and customized payment services. 3PEA’s corporate incentive prepaid cards are changing the way corporations reward, motivate, and engage their current and potential customers, employees, and agents. 3PEA’s customizable prepaid solutions offer significant cost savings while improving brand recognition and customer loyalty. 3PEA’s customers include healthcare companies, major pharmaceutical companies, large multinationals, prestigious universities, and social media companies. PaySign is a registered trademark of 3PEA Technologies, Inc. in the United States and other countries. For more information visit us at paysign.com or follow us on LinkedIn, Twitter and Facebook.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. 3PEA undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.